Alcohol-Related Liver Disease (ALD)

1. Clinical Overview

Summary

Alcohol-Related Liver Disease (ALD) encompasses the full spectrum of hepatic injury caused by chronic excessive alcohol consumption, progressing from simple steatosis (fatty liver) through alcoholic steatohepatitis (ASH) to established fibrosis and ultimately cirrhosis with its attendant complications. [1,2] ALD represents the most common cause of advanced liver disease in Western countries, accounting for approximately 50% of cirrhosis-related deaths in Europe and North America. [3]

The clinical course is highly variable: approximately 90-95% of heavy drinkers develop hepatic steatosis, yet only 20-40% progress to alcoholic hepatitis, and 8-20% ultimately develop cirrhosis. [1,4] This variability reflects the complex interplay between genetic susceptibility (particularly PNPLA3 polymorphisms), environmental cofactors, nutritional status, and drinking patterns. [5]

Acute alcoholic hepatitis (AAH) represents a distinct clinical syndrome characterised by rapid onset of jaundice, fever, and hepatic decompensation superimposed on chronic alcohol-related liver injury. Severe AAH carries a 28-day mortality of 30-50% without treatment, making it one of the most lethal forms of acute liver failure. [6] The cornerstone of management at all stages remains complete abstinence from alcohol, which is the only intervention with proven long-term survival benefit. [7]

Key Facts

Clinical Pearls

The AST:ALT Ratio: In ALD, AST is characteristically greater than ALT, typically in a 2:1 ratio. This occurs because alcohol induces mitochondrial AST release and depletes pyridoxal-5-phosphate (vitamin B6), which is required for ALT synthesis. If ALT exceeds AST, strongly consider alternative diagnoses (viral hepatitis, NAFLD, Wilson's disease). [10]

Maddrey's Discriminant Function (mDF): The most widely used severity score for alcoholic hepatitis. mDF = 4.6 × (PT patient - PT control in seconds) + serum bilirubin (mg/dL). In SI units: mDF = 4.6 × (PT patient - PT control) + bilirubin (μmol/L) / 17.1. Score greater than 32 defines severe disease warranting corticosteroid therapy if no contraindication. [12]

The Lille Score: Calculated at day 7 of prednisolone therapy to assess treatment response. Incorporates age, albumin, initial bilirubin, bilirubin at day 7, PT, and renal failure. Score greater than 0.45 indicates non-response — stop steroids immediately as continued therapy offers no benefit and increases infection risk. [13]

ABIC Score: An alternative prognostic tool. ABIC = (age × 0.1) + (bilirubin × 0.08) + (INR × 0.8) + (creatinine × 0.3). Stratifies into low risk (less than 6.71; 0% 90-day mortality), intermediate (6.71-9.0; 30% mortality), and high risk (greater than 9.0; 75% mortality). [14]

Why This Matters Clinically

ALD is a major and increasing cause of liver-related morbidity and mortality globally, with the UK experiencing a doubling of liver disease deaths over the past 30 years, primarily driven by alcohol. [3] Unlike other major causes of liver disease, ALD is entirely preventable. Early recognition offers opportunities for intervention before irreversible cirrhosis develops.

Severe alcoholic hepatitis requires urgent and accurate severity assessment, as the decision to treat with corticosteroids significantly impacts survival. Equally important is recognising non-responders early (Lille score at day 7) to avoid futile immunosuppression. Cirrhotic complications—portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome—require systematic screening and prophylaxis.

---

2. Epidemiology

Global Burden

Alcohol-related liver disease accounts for approximately 50% of cirrhosis-related mortality in Europe and North America. [3] The World Health Organization attributes 3 million deaths annually to harmful alcohol use globally, with liver disease representing the largest single cause of alcohol-attributable mortality. [1]

Incidence and Prevalence

UK-Specific Data

• ALD accounts for 60-80% of liver disease deaths in the UK [3]
• Hospital admissions for ALD increased by 57% between 2002 and 2012 [3]
• Median age of death from ALD: 52 years (compared to 82 for ischaemic heart disease) [3]
• Trend: Increasing prevalence, particularly in younger age groups and women

Demographics

Risk Factors

Alcohol Consumption

Threshold Doses for Cirrhosis Development:

• Men: Greater than 60-80g ethanol/day (7.5-10 units) for greater than 10 years
• Women: Greater than 20-40g ethanol/day (2.5-5 units) for greater than 10 years [16]

Host Factors Modifying Risk

---

3. Pathophysiology

The Spectrum of Disease

ALD represents a continuum from reversible steatosis to irreversible cirrhosis. Understanding this spectrum is essential for prognostication and management.

DISEASE PROGRESSION SPECTRUM
────────────────────────────────────────────────────────────────────────
                                                                        
 STEATOSIS    →    STEATOHEPATITIS    →    FIBROSIS    →    CIRRHOSIS  
 (Fatty Liver)     (ASH/AAH)              (F1-F4)          (Irreversible)
                                                                        
 ▪ 90-95%          ▪ 20-35%               ▪ Variable       ▪ 8-20%     
 ▪ Reversible      ▪ Partially            ▪ Partially      ▪ Irreversible
 ▪ Asymptomatic      reversible             reversible       structure  
                   ▪ ± symptomatic        ▪ ± symptomatic  ▪ Complications
                                                                        
────────────────────────────────────────────────────────────────────────
                              ABSTINENCE CAN HALT PROGRESSION

Stage 1: Alcoholic Steatosis (Fatty Liver)

Mechanism of Fat Accumulation:

1. Altered NAD+/NADH ratio: Alcohol metabolism by ADH and ALDH generates excess NADH

   • Inhibits fatty acid β-oxidation (requires NAD+)
   • Promotes fatty acid synthesis (NADH drives reactions)
   • Inhibits gluconeogenesis (favours lactate production)

2. SREBP-1c activation: Alcohol upregulates sterol regulatory element-binding protein-1c

   • Increases de novo lipogenesis
   • Enhanced expression of fatty acid synthase (FAS)
   • Enhanced expression of acetyl-CoA carboxylase (ACC)

3. PPARα inhibition: Alcohol suppresses peroxisome proliferator-activated receptor α

   • Reduced fatty acid oxidation
   • Decreased expression of carnitine palmitoyltransferase-1 (CPT-1)

4. Impaired VLDL secretion: Alcohol disrupts very-low-density lipoprotein assembly

   • Accumulation of triglycerides within hepatocytes

Histology: Macrovesicular steatosis (large lipid droplets displacing nucleus), predominantly centrilobular (zone 3). Greater than 5% of hepatocytes containing fat defines steatosis.

Reversibility: Complete resolution within 2-6 weeks of abstinence.

Stage 2: Alcoholic Steatohepatitis (ASH) and Alcoholic Hepatitis (AH)

Key Pathogenic Mechanisms:

1. Acetaldehyde toxicity:

   • Forms protein adducts (acetaldehyde-protein adducts)
   • Triggers immune response (neoantigen formation)
   • Directly damages mitochondria
   • Impairs DNA repair mechanisms

2. Oxidative stress:

   • CYP2E1 induction (microsomal ethanol oxidising system)
   • Generates reactive oxygen species (ROS)
   • Lipid peroxidation (malondialdehyde, 4-hydroxynonenal)
   • Glutathione depletion

3. Gut-liver axis dysfunction (critical in pathogenesis): [18]

   • Alcohol disrupts intestinal tight junctions
   • Increased intestinal permeability ("leaky gut")
   • Bacterial translocation and endotoxaemia (LPS)
   • Portal endotoxaemia activates Kupffer cells

4. Kupffer cell activation:

   • LPS binds TLR4 (Toll-like receptor 4)
   • NFκB activation
   • Pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6, IL-8)
   • Neutrophil recruitment

5. Hepatocyte injury:

   • TNF-α-mediated apoptosis and necrosis
   • Neutrophil infiltration (hallmark of AAH)
   • Mallory-Denk bodies (ubiquitinated keratin aggregates)
   • Ballooning degeneration

Histological Features of Alcoholic Hepatitis:

• Macrovesicular steatosis
• Ballooning degeneration of hepatocytes
• Mallory-Denk bodies (eosinophilic cytoplasmic inclusions)
• Neutrophilic infiltration (lobular and periportal)
• Pericellular/perisinusoidal fibrosis ("chicken-wire" pattern)
• Megamitochondria (giant mitochondria)
• Centrilobular (zone 3) predominance
• Bile ductular reaction in severe cases

Stage 3: Fibrosis

Hepatic Stellate Cell (HSC) Activation:

1. Initiating signals:

   • Oxidative stress products
   • Apoptotic hepatocyte debris
   • Cytokines from Kupffer cells (TGF-β1, PDGF)
   • Acetaldehyde directly activates HSCs

2. Phenotypic transformation:

   • Quiescent HSC → Activated myofibroblast
   • Loss of vitamin A droplets
   • Expression of α-smooth muscle actin (α-SMA)
   • Contractile properties (contributes to portal hypertension)

3. Extracellular matrix deposition:

   • Collagen types I and III (predominantly)
   • Perisinusoidal fibrosis (zone 3 initially)
   • Progressive portal-central bridging
   • Matrix metalloproteinase (MMP) inhibition
   • Tissue inhibitor of metalloproteinase (TIMP) upregulation

Fibrosis Staging:

Reversibility: F1-F3 fibrosis is potentially reversible with sustained abstinence (over months to years). Regression demonstrated in multiple studies with 2+ years abstinence. [7]

Stage 4: Cirrhosis

Architectural Changes:

• Regenerative nodules (micro- or macronodular)
• Complete loss of normal lobular architecture
• Fibrotic septa encircling nodules
• Vascular distortion with intrahepatic shunting
• Reduced functional hepatocyte mass

Pathophysiological Consequences:

1. Portal hypertension (HVPG greater than 5 mmHg):

   • Increased intrahepatic resistance (fibrosis, HSC contraction)
   • Decreased nitric oxide bioavailability
   • Splanchnic vasodilation (NO overproduction in splanchnic bed)
   • Hyperdynamic circulation

2. Synthetic dysfunction:

   • Reduced albumin synthesis (oedema, ascites)
   • Reduced clotting factor synthesis (coagulopathy)
   • Reduced complement synthesis (infection risk)

3. Metabolic dysfunction:

   • Impaired ammonia metabolism (encephalopathy)
   • Hypoglycaemia (reduced gluconeogenesis and glycogenolysis)
   • Endocrine dysfunction (oestrogen metabolism, insulin resistance)

4. Immune dysfunction:

   • Impaired Kupffer cell function
   • Reduced opsonisation
   • Increased infection susceptibility

---

4. Clinical Presentation

Alcoholic Steatosis (Fatty Liver)

Symptoms:

• Usually asymptomatic (incidental finding)
• Mild right upper quadrant discomfort (hepatomegaly)
• Fatigue (non-specific)
• Nausea (may relate to ongoing alcohol use)

Signs:

• Hepatomegaly (smooth, non-tender, soft edge)
• Usually no stigmata of chronic liver disease
• Obesity often coexists

Laboratory:

• Mildly elevated GGT (often the only abnormality)
• AST/ALT may be normal or mildly elevated
• Normal synthetic function (albumin, PT)

Alcoholic Hepatitis

Clinical Syndrome Definition: Rapid onset (usually less than 2 months) of jaundice and liver-related symptoms in a patient with ongoing heavy alcohol consumption or recent cessation, with exclusion of other causes. [2]

Symptoms:

Signs:

Alcoholic Cirrhosis

Compensated Cirrhosis:

• May be asymptomatic for years
• Fatigue, weakness
• Stigmata of chronic liver disease on examination
• Incidental finding of abnormal LFTs or imaging

Decompensated Cirrhosis:

Red Flags Requiring Urgent Action

[!CAUTION] RED FLAGS — Immediate assessment and intervention required:

• Severe jaundice with INR greater than 1.5 and encephalopathy
• Maddrey discriminant function greater than 32 or MELD greater than 21
• Haematemesis or melaena (variceal bleeding)
• Fever with SBP risk (new ascites, abdominal tenderness)
• Rapidly rising creatinine with oliguria (HRS)
• Grade III-IV encephalopathy (somnolence, coma)
• Severe hyponatraemia (less than 125 mmol/L)

---

5. Clinical Examination

Structured Approach

General Inspection:

• Nutritional status (cachexia, muscle wasting, BMI)
• Mental state (confusion, somnolence — encephalopathy grading)
• Stigmata of alcohol abuse (neglect, nicotine staining, tremor)
• Stigmata of chronic liver disease

Hands and Arms:

• Leuconychia (hypoalbuminaemia)
• Clubbing (hepatopulmonary syndrome)
• Palmar erythema
• Dupuytren's contracture
• Asterixis (hepatic flap) — test with arms outstretched, wrists dorsiflexed
• Bruising (coagulopathy)
• Muscle wasting (thenar, forearm)
• Spider naevi (greater than 5 significant)

Face and Neck:

• Scleral icterus (early sign)
• Parotid enlargement (chronic alcohol)
• Fetor hepaticus (sweet, musty breath)
• Gynaecomastia (males — hyperoestrogenaemia)

Abdomen:

• Hepatomegaly: size, consistency (firm in cirrhosis, tender in AAH), edge (nodular)
• Splenomegaly (portal hypertension)
• Ascites: shifting dullness, fluid thrill
• Caput medusae (portal hypertension)
• Abdominal wall collaterals (direction of flow)
• Testicular atrophy (males)

Legs:

• Peripheral oedema
• Muscle wasting
• Proximal myopathy (try to stand from squatting)
• Hair loss

Special Tests

Encephalopathy Grading (West Haven Criteria)

---

6. Investigations

First-Line (Bedside)

• Observations: Temperature (infection), HR, BP (hypotension in decompensation), O2 saturation (hepatopulmonary syndrome)
• Blood glucose: Hypoglycaemia common (impaired gluconeogenesis)
• Urine: Dipstick (UTI exclusion), colour (bilirubin)
• BMI and nutritional assessment

Laboratory Investigations

Liver Function Tests

AST:ALT Ratio Interpretation:

• Greater than 2:1: Strongly suggests ALD [10]
• Greater than 3:1: Highly specific for ALD
• Less than 1:1: Consider NAFLD, viral hepatitis, Wilson's

Synthetic Function

Full Blood Count

Renal Function and Electrolytes

Additional Tests

Prognostic Scoring Systems

Maddrey Discriminant Function (mDF) [12]

Formula:

mDF = 4.6 × (PT patient - PT control in seconds) + Bilirubin (mg/dL)

SI units: mDF = 4.6 × (PT patient - PT control) + Bilirubin (μmol/L) / 17.1

Interpretation:

• mDF less than 32: Mild-moderate AAH (supportive care)
• mDF greater than or equal to 32: Severe AAH (consider corticosteroids)
• mDF greater than 32 untreated: 50% 28-day mortality

MELD Score (Model for End-Stage Liver Disease) [19]

Formula:

MELD = 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43

Minimum values for calculation: 1.0 for each variable
Maximum creatinine: 4.0 mg/dL

Interpretation:

• MELD less than 18: Lower mortality
• MELD 18-21: 20% 90-day mortality
• MELD greater than 21: Greater than 50% 90-day mortality
• MELD greater than 21 can be used as alternative to mDF for steroid decision

ABIC Score [14]

Formula:

ABIC = (Age × 0.1) + (Bilirubin mg/dL × 0.08) + (INR × 0.8) + (Creatinine mg/dL × 0.3)

Risk Stratification:

Glasgow Alcoholic Hepatitis Score (GAHS) [20]

Interpretation:

• GAHS less than 9: Low mortality; steroids not beneficial
• GAHS greater than or equal to 9: Steroids may benefit

Lille Score [13]

Calculated at Day 7 of corticosteroid therapy

Components: Age, albumin at day 0, bilirubin at day 0, bilirubin at day 7, PT, renal failure (creatinine greater than 115 μmol/L)

Online calculator required for precise calculation

Interpretation:

• Lille less than 0.45: Responder — continue steroids for full 28 days
• Lille greater than or equal to 0.45: Non-responder — STOP steroids
• Lille greater than 0.45 carries 75% 6-month mortality [13]

Complete Responder vs Partial Responder:

• Lille less than 0.16: Complete response (best prognosis)
• Lille 0.16-0.45: Partial response
• Lille greater than 0.45: Null response

Imaging

FibroScan Thresholds (in absence of acute inflammation):

• Less than 7 kPa: F0-F1
• 7-10 kPa: F2
• 10-14 kPa: F3
• Greater than 14 kPa: F4 (cirrhosis)

Liver Biopsy

Indications:

• Diagnostic uncertainty (atypical presentation)
• Suspected overlap syndrome (ALD + NASH, ALD + AIH)
• Clinical trial enrollment
• Transplant assessment

Contraindications:

• Severe coagulopathy (INR greater than 1.5, platelets less than 50)
• Significant ascites (transjugular approach preferred)
• Lack of patient cooperation

Histological Features of Alcoholic Hepatitis:

• Steatosis (macrovesicular, zone 3)
• Ballooning degeneration
• Mallory-Denk bodies
• Neutrophilic infiltrate (lobular)
• Pericellular/perisinusoidal fibrosis
• Megamitochondria

Upper GI Endoscopy

Indications:

• All patients with cirrhosis (variceal screening)
• GI bleeding
• Prior to transplant assessment

Findings:

• Oesophageal varices: Grade size, red signs
• Gastric varices: Location (GOV1, GOV2, IGV)
• Portal hypertensive gastropathy

---

7. Management

Management Algorithm

                     ALCOHOL-RELATED LIVER DISEASE
                                   │
                                   ▼
┌────────────────────────────────────────────────────────────────────────┐
│                    ALL PATIENTS: ABSTINENCE                            │
│  ▪ Alcohol liaison/addiction psychiatry referral                      │
│  ▪ Thiamine supplementation (IV Pabrinex if malnourished)             │
│  ▪ Nutritional assessment and support                                  │
└────────────────────────────────────────────────────────────────────────┘
                                   │
                    ┌──────────────┼──────────────┐
                    ▼              ▼              ▼
              ┌──────────┐  ┌───────────┐  ┌─────────────┐
              │ FATTY    │  │ ALCOHOLIC │  │  CIRRHOSIS  │
              │ LIVER    │  │ HEPATITIS │  │             │
              └──────────┘  └───────────┘  └─────────────┘
                    │              │              │
                    ▼              ▼              ▼
           ┌──────────────┐ ┌────────────┐ ┌──────────────────┐
           │ Abstinence   │ │ Calculate  │ │ Complication     │
           │ Lifestyle    │ │ mDF/MELD   │ │ Screening        │
           │ Monitor      │ │ Exclude    │ │ - Varices        │
           │              │ │ infection  │ │ - HCC (6-monthly)│
           └──────────────┘ └────────────┘ └──────────────────┘
                                   │
                    ┌──────────────┴──────────────┐
                    ▼                              ▼
            mDF less than 32 or                    mDF ≥32 or MELD ≥21
            MELD less than 21                              │
                    │                              ▼
                    ▼                    ┌─────────────────────┐
           ┌──────────────┐              │ SEVERE AAH         │
           │ Supportive   │              │ Exclude infection: │
           │ care only    │              │ - Blood cultures   │
           │ - Nutrition  │              │ - CXR              │
           │ - Abstinence │              │ - Urine MCS        │
           └──────────────┘              │ - Ascitic tap      │
                                         └─────────────────────┘
                                                   │
                                         ┌─────────┴─────────┐
                                         ▼                   ▼
                                   No Infection        Infection
                                         │                   │
                                         ▼                   ▼
                               ┌───────────────────┐ ┌──────────────────┐
                               │ PREDNISOLONE      │ │ Treat infection  │
                               │ 40mg OD × 28 days │ │ first            │
                               │ Calculate Lille   │ │ Then reassess    │
                               │ score at Day 7    │ │ for steroids     │
                               └───────────────────┘ └──────────────────┘
                                         │
                               ┌─────────┴─────────┐
                               ▼                   ▼
                         Lille less than 0.45         Lille ≥0.45
                         (Responder)        (Non-responder)
                               │                   │
                               ▼                   ▼
                    ┌───────────────────┐ ┌───────────────────┐
                    │ Continue steroids │ │ STOP STEROIDS     │
                    │ full 28 days      │ │ Best supportive   │
                    │ Taper optional    │ │ care              │
                    └───────────────────┘ │ Consider early    │
                                          │ transplant        │
                                          └───────────────────┘

Acute Management of Severe Alcoholic Hepatitis

Immediate Actions (First 24-48 hours):

1. Resuscitation and stabilisation

   • IV access, fluid resuscitation if hypovolaemic
   • Correct hypoglycaemia (check glucose regularly)
   • Avoid excessive sodium-containing fluids (risk of ascites)

2. Thiamine replacement (URGENT — before any glucose)

   • IV Pabrinex 2 pairs TDS for 3-5 days, then oral thiamine 100mg TDS
   • Prevents Wernicke's encephalopathy
   • Give BEFORE IV glucose administration

3. Infection screen (MANDATORY before steroids)

   • Blood cultures (×2 sets)
   • Urine MCS
   • Chest X-ray
   • Diagnostic ascitic tap if ascites present (cell count, culture, albumin)
   • Consider C-reactive protein, procalcitonin

4. Nutritional assessment

   • Most patients severely malnourished
   • Dietitian referral
   • Target: 35-40 kcal/kg/day, protein 1.2-1.5 g/kg/day
   • Enteral preferred over parenteral
   • Refeeding syndrome risk — monitor phosphate, potassium, magnesium

5. Calculate severity scores

   • Maddrey DF
   • MELD score
   • GAHS
   • ABIC score

6. Correct coagulopathy if bleeding

   • Vitamin K 10mg IV (once)
   • FFP/PCC only if active bleeding (not to improve INR for biopsy alone)

Pharmacological Management

Corticosteroids for Severe Alcoholic Hepatitis [8]

Indication:

• mDF greater than or equal to 32 OR MELD greater than or equal to 21
• AND no active infection
• AND no uncontrolled GI bleeding
• AND no multi-organ failure

Regimen:

• Prednisolone 40mg once daily orally for 28 days
• (Equivalent: Methylprednisolone 32mg IV if unable to take oral)
• No taper required (though some centres taper over 2-4 weeks)

Contraindications:

• Active infection (including SBP, pneumonia, UTI)
• Uncontrolled GI bleeding
• Severe renal failure requiring dialysis
• Multi-organ failure
• Hepatitis B reactivation
• Active tuberculosis

Monitoring:

• Lille score at Day 7 — critical decision point
• Daily glucose (steroids cause hyperglycaemia)
• Infection surveillance throughout

STOPAH Trial Key Findings: [8]

• Prednisolone reduced 28-day mortality (14% vs 17.5%, OR 0.72 p=0.06, became significant on intention-to-treat)
• No mortality benefit at 90 days or 1 year
• Pentoxifylline showed no benefit at any time point
• Combination therapy (prednisolone + pentoxifylline) no better than prednisolone alone

Lille Score Response Interpretation: [13]

• Lille less than 0.16: Complete response — 15% 6-month mortality
• Lille 0.16-0.45: Partial response — 25% 6-month mortality
• Lille greater than or equal to 0.45: Null response — STOP steroids — 75% 6-month mortality

Pentoxifylline [8]

Current Status: NOT RECOMMENDED

• STOPAH trial definitively showed no mortality benefit
• Previously used as alternative when steroids contraindicated
• Mechanism: TNF-α inhibitor
• Dose (historical): 400mg TDS for 28 days

N-Acetylcysteine (NAC)

Evidence: Adjunct to steroids may reduce 1-month mortality and infection risk [21]

• Improved 1-month survival when combined with prednisolone
• No benefit at 6 months
• May reduce hepatorenal syndrome and infections

Regimen: 150mg/kg over 30 min, then 50mg/kg over 4h, then 100mg/kg over 16h (as per paracetamol poisoning protocol)

Management of Cirrhosis Complications

Ascites

First-Line Management:

1. Sodium restriction: Less than 2g/day (less than 88 mmol/day)
2. Diuretics:
   • Spironolactone 100mg OD (up to 400mg)
   • Furosemide 40mg OD (up to 160mg) if inadequate response
   • Ratio: 100mg spironolactone : 40mg furosemide
   • Target weight loss: 0.5kg/day (no oedema) or 1kg/day (with oedema)

Refractory Ascites:

• Large volume paracentesis (LVP) with albumin replacement
  • Albumin 6-8g per litre removed if greater than 5L
• TIPS (transjugular intrahepatic portosystemic shunt)
• Consider transplant referral

Spontaneous Bacterial Peritonitis (SBP)

Diagnosis:

• Ascitic fluid neutrophil count greater than 250 cells/mm³
• Positive ascitic fluid culture (but may be culture-negative)

Treatment:

• IV ceftriaxone 2g OD or IV co-amoxiclav
• Duration: 5-7 days
• IV albumin: 1.5g/kg day 1, 1g/kg day 3 (reduces HRS and mortality)

Secondary Prophylaxis:

• Norfloxacin 400mg OD or ciprofloxacin 500mg OD lifelong
• Alternative: co-trimoxazole 960mg OD 5 days/week

Primary Prophylaxis:

• Ascitic protein less than 15g/L with advanced liver disease
• After GI bleeding
• Norfloxacin 400mg OD or ciprofloxacin 500mg OD

Variceal Bleeding

Acute Management:

1. Resuscitation: IV access, blood products (target Hb 70-80g/L), correct coagulopathy
2. Vasoactive therapy: Terlipressin 2mg IV bolus then 1-2mg q4h (or octreotide/somatostatin)
3. IV PPI: Pantoprazole 80mg bolus
4. Antibiotics: Ceftriaxone 1g IV OD (reduces rebleeding and mortality)
5. Endoscopy: Within 12 hours — band ligation (preferred) or sclerotherapy
6. Balloon tamponade: Bridge to definitive therapy if massive bleeding
7. TIPS: Rescue therapy if endoscopic therapy fails; early TIPS in high-risk patients

Secondary Prophylaxis:

• Non-selective beta-blocker (propranolol or carvedilol) + EVL repeat sessions
• Target: Resting HR 55-60 bpm or 25% reduction

Primary Prophylaxis (varices without bleeding):

• Large varices or red signs: NSBB (propranolol 20mg BD, titrate) or EVL
• Small varices with high risk: NSBB

Hepatic Encephalopathy

Precipitant Identification:

• Infection (most common)
• GI bleeding
• Constipation
• Electrolyte disturbance (hyponatraemia, hypokalaemia)
• Dehydration
• Sedative drugs
• Dietary protein excess
• TIPS dysfunction

Treatment:

1. Treat precipitant (antibiotics for infection, correct electrolytes)
2. Lactulose: 15-30mL 2-4× daily, titrate to 2-3 soft stools/day
3. Rifaximin: 550mg BD (for recurrent HE) — reduces HE recurrence by 58% [22]
4. Nutritional support: Do NOT restrict protein (1.2-1.5g/kg/day)
5. Zinc supplementation: If deficient
6. Avoid sedatives: Especially benzodiazepines, opioids

Grading-Based Approach:

• Grade I-II: Oral lactulose, treat precipitant
• Grade III-IV: Consider ITU, airway protection, NG lactulose, IV fluids

Hepatorenal Syndrome (HRS) [23]

Diagnosis (ICA 2015 Criteria):

• Cirrhosis with ascites
• Creatinine greater than 133 μmol/L (1.5 mg/dL)
• No improvement after 48h of diuretic withdrawal and albumin expansion (1g/kg up to 100g)
• Absence of shock
• No nephrotoxic drugs
• Absence of parenchymal kidney disease (proteinuria less than 500mg/day, no haematuria, normal ultrasound)

Classification:

• HRS-AKI (formerly Type 1): Rapid deterioration, doubling of creatinine within 2 weeks
• HRS-CKD (formerly Type 2): Gradual, associated with refractory ascites

Treatment:

1. Stop diuretics, nephrotoxics
2. Volume expansion: Albumin 1g/kg (max 100g)
3. Terlipressin + albumin: [23]
   • Terlipressin 0.5-1mg IV q4-6h (max 2mg q4h)
   • Albumin 20-40g daily
   • Continue until creatinine less than 133 μmol/L or max 14 days
   • Response rate: 40-50%
4. Noradrenaline (alternative in ITU)
5. TIPS: Consider if stable enough
6. Liver transplant: Definitive treatment; prioritise referral

Hepatocellular Carcinoma Surveillance

Who to Screen:

• All patients with cirrhosis (any aetiology)
• ALD patients with advanced fibrosis (F3)

Modality:

• Ultrasound ± AFP every 6 months

If Lesion Detected:

• CT triple-phase or MRI with liver-specific contrast
• Typical HCC: Arterial enhancement + venous/delayed washout
• Biopsy rarely needed if imaging characteristic

Liver Transplantation [11,24]

Indications

• Decompensated cirrhosis (ascites, variceal bleeding, HE, HRS) with poor prognosis
• HCC within Milan criteria (single lesion less than or equal to 5cm, or up to 3 lesions all less than or equal to 3cm)
• MELD score greater than 15 (survival benefit from transplant)
• Severe AAH non-responders (selected centres)

The "6-Month Rule"

Traditional Approach:

• Required 6 months of documented abstinence before transplant listing
• Based on: Allow liver recovery, predict post-transplant abstinence, fair allocation

Evolving Practice:

• Landmark study (Mathurin, NEJM 2011) showed early transplant in selected AAH non-responders had similar outcomes [11]
• Selection criteria included first liver decompensation, supportive family, commitment to abstinence
• 6-month survival 77% (vs 23% matched controls)
• UK now offers early transplant in selected AAH cases

Post-Transplant Outcomes:

• 5-year survival: 70-80% (comparable to other indications)
• Alcohol relapse rate: 10-30%
• Harmful relapse (affecting graft): 10-15%
• Excellent outcomes with good psychosocial support

Psychosocial Assessment

All transplant candidates require:

• Addiction psychiatry evaluation
• Assessment of insight and commitment
• Social support network evaluation
• Mental health screen (depression, anxiety common)
• Ability to adhere to post-transplant regimen

Abstinence Support

Pharmacological:

Non-Pharmacological:

• Brief intervention (5 mins effective in primary care)
• Alcohol liaison nurses
• Motivational interviewing
• Cognitive behavioural therapy
• Alcoholics Anonymous / SMART Recovery
• Inpatient detoxification if required
• Relapse prevention programmes

---

8. Complications

Complications by Timeframe

Immediate (Days)

Early (Weeks-Months)

Late (Months-Years)

---

9. Prognosis and Outcomes

Natural History by Stage

Mortality Data

Severe Alcoholic Hepatitis:

• Untreated (mDF greater than 32): 50% 28-day mortality
• Prednisolone-treated: 20-30% 28-day mortality [8]
• Lille responders: 15% 6-month mortality [13]
• Lille non-responders: 75% 6-month mortality [13]

Cirrhosis:

• Compensated: 1-2% annual mortality
• After first decompensation: 20% 1-year mortality
• With continued drinking: 5-year survival 30%
• With abstinence: 5-year survival 60-70%

Prognostic Factors

Good Prognosis:

• Early stage (steatosis, mild hepatitis)
• Sustained abstinence
• Good nutritional status
• Lille responder (less than 0.45)
• Lower MELD score (less than 18)
• No encephalopathy
• No renal impairment
• Good social support

Poor Prognosis:

• mDF greater than 32 or MELD greater than 21
• Lille non-responder
• Hepatorenal syndrome
• Grade III-IV encephalopathy
• Infection/sepsis
• Severe hyponatraemia
• Continued alcohol use
• Malnutrition
• Age greater than 65
• HCC development

---

10. Prevention and Screening

Primary Prevention

Population Level:

• Minimum unit pricing (effective in Scotland)
• Taxation and availability regulation
• Advertising restrictions
• Brief interventions in primary care

Individual Level:

• Alcohol screening (AUDIT-C, CAGE)
• Brief intervention (5-minute advice effective)
• Referral to specialist alcohol services
• Treatment of alcohol use disorder

Secondary Prevention (Disease Progression)

• Abstinence: Only intervention proven to prevent progression
• Hepatitis B vaccination: All non-immune patients
• Obesity management: Synergistic hepatotoxicity
• Smoking cessation: Independent risk factor for fibrosis progression
• HCV treatment: If co-infected (interferon-free regimens safe)

Tertiary Prevention (Complication Prevention in Cirrhosis)

• Variceal surveillance (OGD at diagnosis, every 2-3 years if no varices)
• HCC surveillance (US ± AFP every 6 months)
• SBP prophylaxis (if prior SBP or low-protein ascites)
• Bone density screening (osteoporosis common)
• Nutritional support

---

11. Evidence and Guidelines

Key Guidelines

1. EASL Clinical Practice Guidelines: Alcohol-Related Liver Disease (2018) — Comprehensive European recommendations on diagnosis, staging, and management. [1]

2. ACG Clinical Guideline: Alcoholic Liver Disease (2018) — American College of Gastroenterology recommendations with focus on US practice. [2]

3. NICE NG50: Cirrhosis in over 16s (2016) — Assessment and management of cirrhosis including ALD-specific considerations. [25]

4. BSG/BASL Decompensated Cirrhosis Guidelines (2020) — UK guidance on acute decompensation management.

5. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for liver disease severity and prognosis — FibroScan and other non-invasive markers.

Landmark Trials

STOPAH Trial (2015) — Steroids or Pentoxifylline for Alcoholic Hepatitis [8]

• Design: 2×2 factorial RCT, n=1103
• Intervention: Prednisolone, pentoxifylline, both, or neither
• Key findings:
  • Prednisolone reduced 28-day mortality (non-significant trend, OR 0.72, p=0.06)
  • Pentoxifylline NO benefit
  • No mortality difference at 90 days or 1 year
  • Combination no better than prednisolone alone
• Clinical impact: Supports steroids for severe AAH; pentoxifylline abandoned

Lille Study (2007) — Early Change in Bilirubin and Prognosis [13]

• Developed Lille score to identify steroid non-responders at day 7
• Non-responders (Lille greater than 0.45) have no benefit from continued steroids
• Clinical impact: Standardised day 7 reassessment; stop steroids in non-responders

Mathurin et al (2011) — Early Liver Transplant for Severe Alcoholic Hepatitis [11]

• Selected AAH non-responders transplanted without 6-month abstinence
• 6-month survival 77% vs 23% in matched controls
• Clinical impact: Challenged 6-month rule; early transplant now offered in selected centres

CONFIRM Trial (2022) — Combination of Steroids and NAC [21]

• NAC + prednisolone vs prednisolone alone
• Improved 28-day survival with combination
• Reduced hepatorenal syndrome and infections
• Clinical impact: Consider NAC as adjunct therapy

Evidence Strength Summary

---

12. Exam-Focused Section

Common Exam Questions

MRCP/FRACP Written:

1. "What are the causes and risk factors for alcohol-related liver disease?"
2. "Describe the pathophysiology of alcoholic hepatitis"
3. "How would you assess severity in alcoholic hepatitis?"
4. "What is the evidence for corticosteroids in alcoholic hepatitis?"
5. "Describe the management of hepatorenal syndrome"

Clinical/PACES:

1. "Examine this patient's abdomen" — chronic liver disease signs
2. "Examine this patient's hands and face" — stigmata of CLD
3. "Interpret these liver function tests" — AST:ALT ratio
4. "This patient has jaundice and ascites. How would you manage them?"

Viva Points

Opening Statement: "Alcohol-related liver disease encompasses a spectrum from fatty liver through alcoholic hepatitis to cirrhosis, caused by chronic excessive alcohol consumption. It is the leading cause of liver-related mortality in Western countries, and abstinence is the cornerstone of management at all stages."

Key Facts to State:

• 90% develop fatty liver; 20% progress to cirrhosis
• Severe AAH defined by mDF greater than 32 or MELD greater than 21
• STOPAH trial: prednisolone reduces 28-day mortality; pentoxifylline does not
• Lille score at day 7: greater than 0.45 = stop steroids (no benefit, infection risk)
• 6-month abstinence for transplant is traditional but evolving

Classification to Quote:

• West Haven criteria for hepatic encephalopathy
• Child-Pugh score for cirrhosis severity
• MELD score for transplant prioritisation
• Lille score for steroid response

Common Mistakes That Fail Candidates

• Missing the AST greater than ALT pattern in ALD
• Starting steroids without excluding infection
• Continuing steroids when Lille greater than 0.45
• Restricting protein in hepatic encephalopathy (evidence against this)
• Missing variceal surveillance in cirrhosis
• Using pentoxifylline (outdated practice)
• Not calculating mDF or MELD in acute presentation
• Forgetting Pabrinex before glucose in malnourished alcoholics
• Missing the differential: NAFLD if ALT greater than AST

Model Answers

Q: A 48-year-old man presents with jaundice, ascites, and confusion. He has been drinking heavily for 20 years. How would you approach this case?

A: "This presentation suggests decompensated alcohol-related liver disease with acute alcoholic hepatitis. My immediate priorities would be:

First, ABC assessment and resuscitation. I would secure IV access, check blood glucose (hypoglycaemia common), and give IV Pabrinex urgently before any glucose-containing fluids to prevent Wernicke's encephalopathy.

Second, I would assess disease severity by calculating the Maddrey discriminant function and MELD score. If mDF is greater than 32 or MELD greater than 21, this is severe alcoholic hepatitis.

Third, before considering steroids, I must exclude infection as a contraindication. I would send blood cultures, urine cultures, chest X-ray, and perform a diagnostic ascitic tap with cell count and culture. Ascitic neutrophils greater than 250 would indicate SBP.

For the confusion, I would grade the encephalopathy using West Haven criteria and look for precipitants — infection, GI bleeding, electrolyte disturbance, constipation. I would start lactulose aiming for 2-3 soft stools daily.

If infection is excluded and mDF is greater than 32, I would start prednisolone 40mg daily for 28 days. I would calculate the Lille score at day 7 — if greater than 0.45, I would stop steroids as they offer no benefit and increase infection risk.

Nutritional support is critical — most of these patients are malnourished. I would target 35-40 kcal/kg/day with 1.2-1.5g protein/kg/day.

Finally, I would involve the alcohol liaison service for abstinence support and consider early hepatology referral for transplant assessment if the patient is a non-responder to steroids."

---

13. Patient/Layperson Explanation

What is Alcohol-Related Liver Disease?

Your liver is an amazing organ that does hundreds of essential jobs — filtering toxins from your blood, making proteins, storing energy, and helping with digestion. When you drink alcohol, your liver works hard to process it. But if you drink too much over time, the liver becomes damaged.

Alcohol-related liver disease (ALD) happens in stages:

1. Fatty liver: First, fat builds up in your liver cells. This happens to almost everyone who drinks heavily. Usually there are no symptoms, and it completely reverses if you stop drinking.

2. Alcoholic hepatitis: With continued heavy drinking, your liver becomes inflamed. You may feel very tired, lose your appetite, and your skin and eyes may turn yellow (jaundice). This can be mild or very serious.

3. Cirrhosis: Over many years, scar tissue replaces healthy liver tissue. The liver becomes hard and shrunken. This is permanent damage that cannot be reversed, though stopping drinking prevents it getting worse.

Why Does This Matter?

Severe alcoholic hepatitis can be life-threatening — without treatment, about half of people with severe disease die within a month. Even with treatment, it remains a very serious condition.

Cirrhosis leads to serious complications:

• Fluid building up in your tummy (ascites)
• Confusion and drowsiness (because toxins build up)
• Vomiting blood (from swollen veins in your gullet)
• Kidney problems
• Liver cancer

How Is It Treated?

The most important treatment is stopping drinking completely. This is the only thing proven to improve long-term survival. Even with cirrhosis, stopping drinking dramatically improves your outlook.

Other treatments include:

• Steroids: For severe alcoholic hepatitis, steroid tablets can reduce inflammation and improve survival
• Good nutrition: Many people with ALD are malnourished. Eating well helps your liver heal
• Medicines for complications: Water tablets for fluid, laxatives for confusion
• Liver transplant: For people with end-stage disease who have stopped drinking

When to Get Help Urgently

See a doctor immediately if you notice:

• Yellowing of your skin or the whites of your eyes
• Swelling of your tummy
• Confusion or unusual drowsiness
• Vomiting blood or passing black, tarry stools
• Fever with tummy pain

Support for Stopping Drinking

Stopping drinking is hard, but help is available:

• Your GP can refer you to specialist alcohol services
• Medicines can help reduce cravings
• Support groups like Alcoholics Anonymous help many people
• Alcohol liaison nurses in hospitals provide support
• The British Liver Trust has resources and support groups

---

14. References

Primary Guidelines

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi:10.1016/j.jhep.2018.03.018

2. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194. doi:10.1038/ajg.2017.469

Epidemiology and Pathophysiology

3. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958):1953-1997. doi:10.1016/S0140-6736(14)61838-9

4. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16. doi:10.1038/s41572-018-0014-7

5. Trépo E, Gustot T, Degré D, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol. 2011;55(4):906-912. doi:10.1016/j.jhep.2011.01.028

Alcoholic Hepatitis and Severity Scores

6. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199. doi:10.1016/0016-5085(78)90401-8

7. Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987-990. doi:10.1016/s0140-6736(95)91685-7

Key Trials

8. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619-1628. doi:10.1056/NEJMoa1412278

9. Department of Health. UK Chief Medical Officers' Low Risk Drinking Guidelines. 2016. Available at: https://www.gov.uk/government/publications/alcohol-consumption-advice-on-low-risk-drinking

10. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336-339. doi:10.1093/alcalc/agh074

11. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790-1800. doi:10.1056/NEJMoa1105703

12. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110(9):685-690. doi:10.7326/0003-4819-110-9-685

13. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354. doi:10.1002/hep.21607

14. Dominguez M, Rincón D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103(11):2747-2756. doi:10.1111/j.1572-0241.2008.02104.x

Cirrhosis Complications

15. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380. doi:10.1002/hep.29086

16. Becker U, Deis A, Sørensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-1029. doi:10.1002/hep.510230513

17. Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240. doi:10.1136/bmj.c1240

18. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148(1):30-36. doi:10.1053/j.gastro.2014.10.042

19. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353-358. doi:10.1002/hep.20503

20. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8):1174-1179. doi:10.1136/gut.2004.050781

21. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781-1789. doi:10.1056/NEJMoa1101214

22. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081. doi:10.1056/NEJMoa0907893

23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024

24. Addolorato G, Bataller R, Burra P, et al. Liver Transplantation for Alcoholic Liver Disease: A Systematic Review. J Hepatol. 2016;65(3):619-630. doi:10.1016/j.jhep.2016.05.040

25. National Institute for Health and Care Excellence. Cirrhosis in over 16 s: assessment and management. NICE guideline [NG50]. 2016. Available at: https://www.nice.org.uk/guidance/ng50

Further Resources

• British Liver Trust: britishlivertrust.org.uk
• Alcohol Change UK: alcoholchange.org.uk
• NHS Alcohol Support: nhs.uk/live-well/alcohol-advice
• Drinkaware: drinkaware.co.uk

---

Last Reviewed: 2025-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.